Payment overview · 2025
General Payments
$59,371.31
207 reported records · 19 companies
Healthcare provider profile · identity verified
Anthony Jones, MD
Allopathic & Osteopathic Physicians|Family Medicine · OAKLAND, CA · NPI 1538246194
Verified facts
What the public records show
CMS Open Payments records show Anthony Jones, MD received $59,371.31 in general payments during 2025 across 207 reported records.
Gilead Sciences, Inc. accounted for 95.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Creon, Descovy, Dovato, Eliquis, Farxiga, Jardiance, Linzess, Mytesi, Ozempic, Paxlovid, Pifeltro, Rukobia, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Pifeltro by this doctor in 2024.
Napo Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mytesi as an associated drug or biological on 1178 records involving 562 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mytesi by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $56,649.30 | 95.4% | 92 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $920.44 | 1.6% | 40 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $387.56 | 0.7% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $354.81 | 0.6% | 14 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $203.60 | 0.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.04 | 0.3% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $166.16 | 0.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.34 | 0.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.15 | 0.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.66 | 0.1% | 3 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $57.51 | 0.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.31 | 0.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.92 | 0.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.35 | 0.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.33 | 0.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.16 | 0.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.78 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.73 | 0.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.16 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,952.50 | 14 |
| Travel and Lodging | $14,308.92 | 22 |
| Consulting Fee | $5,320.00 | 1 |
| Food and Beverage | $4,789.89 | 170 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $22,957.57 | 28 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $11,587.52 | 16 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $9,148.11 | 10 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $298.22 | 11 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $293.65 | 12 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $235.33 | 9 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $203.60 | 10 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $203.60 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.37 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.85 | 4 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $93.24 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.19 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.75 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.15 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $62.66 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.31 | 2 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $57.51 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.92 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.35 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.79 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.33 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 289 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Descovy descovy |
2025 | Descovy | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mytesi mytesi |
2025 | Mytesi | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
289 | 29 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Napo Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Mytesi open payments reported associated product |
CMS Open Payments — General Payments 1178 supporting records · 562 recipient NPIs · example record 1223618503 |
Mytesi · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 90 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 289 | 29 |
| Gabapentin | Gabapentin | 221 | 42 |
| Losartan Potassium | Losartan Potassium | 205 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 39 |
| Metformin Hcl | Metformin Hcl | 181 | 47 |
| Lisinopril | Lisinopril | 169 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 41 |
| Tivicay | Dolutegravir Sodium | 143 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 23 |
| Montelukast Sodium | Montelukast Sodium | 114 | 25 |
| Famotidine | Famotidine | 105 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 33 |
| Acyclovir | Acyclovir | 100 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 32 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 93 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 21 |
| Furosemide | Furosemide | 86 | 20 |
| Lorazepam | Lorazepam | 85 | 23 |
| Chlorthalidone | Chlorthalidone | 83 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 19 |
| Rybelsus | Semaglutide | 79 | 15 |
| Ozempic | Semaglutide | 78 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 76 | 22 |
| Pifeltro | Doravirine | 76 | suppressed |
| Omeprazole | Omeprazole | 75 | 18 |
| Descovy | Emtricitabine/Tenofov Alafenam | 73 | suppressed |
| Ibuprofen | Ibuprofen | 73 | 22 |
| Dovato | Dolutegravir Sodium/Lamivudine | 72 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 72 | 18 |
| Testosterone | Testosterone | 70 | suppressed |
| Baclofen | Baclofen | 66 | 14 |
| Eliquis | Apixaban | 66 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 20 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 12 |
| Bupropion Xl | Bupropion Hcl | 60 | suppressed |
| Potassium Chloride | Potassium Chloride | 60 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | suppressed |
| Trulicity | Dulaglutide | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | 11 |
| Trazodone Hcl | Trazodone Hcl | 51 | 17 |
| Tramadol Hcl | Tramadol Hcl | 48 | 16 |
| Diazepam | Diazepam | 47 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 47 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | suppressed |
| Allopurinol | Allopurinol | 43 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | suppressed |
| Simvastatin | Simvastatin | 41 | suppressed |
| Creon | Lipase/Protease/Amylase | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Maraviroc | Maraviroc | 36 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Mytesi | Crofelemer | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 15 |
| Azithromycin | Azithromycin | 33 | 20 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Isentress | Raltegravir Potassium | 31 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lamivudine | Lamivudine | 22 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Cabenuva | Cabotegravir/Rilpivirine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Dronabinol | Dronabinol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59,371.31 · 207 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, APRETUDE, Biktarvy, CABENUVA, COMIRNATY, CONTRAVE, CREON, DOVATO, Descovy, EGRIFTA, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, Kerendia, LINZESS, MAVYRET, MOUNJARO, Mytesi, NURTEC ODT, Ozempic, PAXLOVID, PIFELTRO, PREVNAR 20, QULIPTA, RUKOBIA, Rybelsus, SHINGRIX, TROGARZO, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, Yeztugo, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error